We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ALX Oncology Holdings Inc. (ALXO - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ALX Oncology Holdings Inc. is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ALX Oncology Holdings Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALXO's full-year earnings has moved 11.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALXO has returned 7.2% so far this year. Meanwhile, the Medical sector has returned an average of -4.9% on a year-to-date basis. This means that ALX Oncology Holdings Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 18.6%.
In Ginkgo Bioworks Holdings, Inc.'s case, the consensus EPS estimate for the current year increased 12% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ALX Oncology Holdings Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual stocks and currently sits at #66 in the Zacks Industry Rank. This group has lost an average of 12.7% so far this year, so ALXO is performing better in this area. Ginkgo Bioworks Holdings, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track ALX Oncology Holdings Inc. and Ginkgo Bioworks Holdings, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ALX Oncology Holdings Inc. (ALXO - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ALX Oncology Holdings Inc. is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ALX Oncology Holdings Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALXO's full-year earnings has moved 11.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALXO has returned 7.2% so far this year. Meanwhile, the Medical sector has returned an average of -4.9% on a year-to-date basis. This means that ALX Oncology Holdings Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 18.6%.
In Ginkgo Bioworks Holdings, Inc.'s case, the consensus EPS estimate for the current year increased 12% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ALX Oncology Holdings Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual stocks and currently sits at #66 in the Zacks Industry Rank. This group has lost an average of 12.7% so far this year, so ALXO is performing better in this area. Ginkgo Bioworks Holdings, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track ALX Oncology Holdings Inc. and Ginkgo Bioworks Holdings, Inc. These stocks will be looking to continue their solid performance.